Lumoptik Eye: A Closer Look

Click to enlarge

Our Precision Eye Guidance System represents an exciting opportunity to present target-specific therapy to the eye. The ability to safely and effectively deliver pharmacologic or cell-based therapy to the suprachoroidal or sub-retinal space would represent a major advance in the treatment of blinding diseases of the eye, most of which involve the retina or macula (the area of the retina responsible for fine, central vision.)

Diabetic eye disease (diabetic retinopathy/DR) is the most common cause of blindness in working Americans; age-related macular degeneration (AMD) is the most common cause in Americans over 65; vein/vascular occlusive disease is a common complication of atherosclerosis, hypertension, and glaucoma; retinopathy of prematurity (ROP) is the leading cause of blindness in infants; and the most common primary eye tumor is melanoma and metastatic neoplasia, which frequently localizes to the retina and associated layers.

For age-related macular degeneration, a significant market exists for new methods of treatment that will reduce the therapeutic burden of monthly injections. New drugs, molecules, biologics, and cell-based strategies will all benefit from being placed in close proximity to the disease. In the United States, the number of people living with macular degeneration today is similar to that of those who have all types of cancer. As many as 11 million people in the US have some form of AMD. This number is expected to double to nearly 22 million by 2050.

Our device, which can identify the tiniest changes in small tissue planes, has the potential to revolutionize therapy, decrease blindness and improve patient outcomes, and substantially reduce costs on a global scale.

Home   |   Market Opportunities   |   Medical Applications   |   Management Team   |   Lumoptik Eye   |   Contact Us
© 2019 Lumoptik, Inc., All Rights Reserved   |   Web Site Developed by Alt Media Studios   |   Brand identity and copywriting by James Marketing